Clinical Utility of PCR in Complicated Urinary Tract Infections: A Paradigm Shift in Diagnostics and Management

In the realm of medical diagnostics, the evolution of technology often compels a re-evaluation of established practices. Just as the direct examination of a patient's urine for a “honey taste” to diagnose diabetes mellitus has been superseded by sophisticated scientific advances,1 so too must the diagnostic approach to complicated urinary tract infections (cUTIs) evolve beyond the inherent limitations of conventional culture and sensitivity (C&S) testing. Complicated UTIs, defined as urinary tract infections occurring in the presence of host risk factors such as indwelling catheters, urolithiasis, diabetes mellitus, immunosuppression, or structural and functional urinary tract abnormalities, remain a formidable challenge, characterized by complex microbial etiologies, escalating antimicrobial resistance, and significant risks of morbidity and mortality.2 The prolonged turnaround times (TAT) inherent in C&S often delay the initiation of effective, targeted therapy, leading to suboptimal patient outcomes and contributing to the broader crisis of antibiotic resistance. In this critical landscape, PCR-based diagnostics have emerged as a transformative solution, providing rapid and comprehensive pathogen identification, as well as resistance gene detection. The robust evidence from the US multicenter randomized trial (NCT06996301) provides compelling support for a paradigm shift in cUTI management, necessitating a reevaluation of current diagnostic and therapeutic approaches. THE FOUNDATIONAL ADVANCE: INSIGHTS FROM THE NCT06996301 TRIAL The NCT06996301 trial (Advarra IRB ID: Pro00071764), a large-scale, investigator-blinded, multicenter randomized study involving 773 adult cUTI patients across 6 US sites, directly compared PCR-guided management against conventional C&S testing.3 A critical aspect of its robust design was the dual-testing approach: both PCR and C&S tests were performed for all patients at baseline and end of study (EOS), irrespective of their assigned treatment arm. Investigators, however, were blinded to the comparator test results, ensuring that treatment decisions were based solely on the randomly assigned diagnostic method. This meticulous design enabled an unparalleled side-by-side comparison of diagnostic accuracy, therapeutic guidance, and clinical outcomes, providing invaluable insight into the clinical utility of each method.3 The findings from the NCT06996301 trial, published in 3 parts, collectively underscore PCR's significant advantages over C&S across multiple critical domains, challenging the traditional reliance on slower, less comprehensive methods. Part I of the trial demonstrated that PCR-guided therapy led to significantly improved favorable clinical outcomes (defined as resolution of at least one symptom and absence of retreatment) in 88.08% of PCR patients compared with 78.11% of C&S patients (P = .011).3 The overall microbial eradication efficiency was better among patients treated based on PCR results vs those treated based on C&S, however, without a statistically significant effect (62.18% vs 56.21%, P = .24). Substantial operational benefits complemented this clinical superiority; investigator satisfaction scores were markedly higher for PCR (mean 4.6/5) compared with C&S (3.8/5; P < .001), reflecting a more streamlined and effective diagnostic process. Furthermore, the mean diagnostic TAT was nearly halved with PCR (49.7 hours) vs C&S (104.4 hours; P < .001).3 This rapid TAT is crucial, enabling earlier initiation of appropriate, targeted therapy, thereby minimizing patient morbidity, reducing the risk of complications, and optimizing healthcare resource utilization. Part II of the study examined diagnostic concordance, reporting 88.1% sensitivity and 62.9% specificity at EOS. The lower specificity reflects PCR's ability to detect fastidious or polymicrobial infections that C&S misses, particularly in a symptomatic cUTI cohort with underlying risk factors, rather than false positives. Indeed, 174 PCR+/C&S– symptomatic cases at baseline achieved 77.45% favorable clinical outcomes, and 53.92% microbiological eradication, suggesting these represented true infections requiring treatment. Additional analysis on antimicrobial use and microbiological aspects revealed that the PCR group received more oral medication-based treatments, while the C&S group received other forms (intramuscular and even bladder irrigation).4 An ad hoc analysis (Part III) of the trial's data by Kardjadj et al5 further evaluated pathogen detection, resistance profiling, and clinical outcomes. PCR detected polymicrobial infections in 43.52% of samples compared with 31.95% by C&S (P = .033). Patients in the C&S arms with undetected polymicrobial infections had a significantly higher clinical failure rate (33.33%, P = .041) compared with those with concordant polymicrobial infection identification by both methods (22.22%). PCR also detected additional pathogens in 54.44% of cases in the C&S arm, where clinical failure was significantly higher when C&S missed pathogens (28.26% vs 14.29%, P = .015). Similarly, when C&S failed to detect phenotypic resistance (compared with PCR), clinical failure occurred in 50% of cases, compared with 13.22% (P = .001) when resistance detection was concordant (PCR and C&S). Beyond clinical efficacy, the economic and regulatory landscape strongly supports the adoption of PCR in cUTI management, presenting a compelling argument for its integration into standard practice. The trial's findings align seamlessly with the Molecular Diagnostic Services (MolDX) Program's coverage criteria, which mandate that expanded syndromic panels must demonstrably impact clinical management and improve patient outcomes.6 A comprehensive review by Aberger et al7 of 8 real-world evidence (RWE) studies demonstrates that broad panel PCR platforms consistently outperform culture alone, identifying fastidious and polymicrobial pathogens missed by routine methods, and enabling earlier, targeted therapy that reduces empirical antibiotic use and improves clinical outcomes. Moreover, Aberger et al7 review confirms that the PCR panel (DocLab 2.0 UTM) used in NCT06996301 satisfies MolDX's stringent analytical and clinical validity criteria, achieving high accuracy, substantially shortening time to appropriate therapy, and delivering measurable gains in patient outcomes. RWE from Ko et al8 offers a compelling economic and clinical argument for integrating PCR into cUTI management. In a Medicare cohort of patients with complicated or recurrent UTIs, PCR-guided diagnostics reduced the incidence of recurrence from 72.0% to 65.2%, while cutting mean 1-year UTI-related costs from $1131 to $629 per patient, a statistically significant saving of $502 (P = .004). Moreover, nonoutpatient resource utilization (including hospitalizations and emergency visits) dropped from 53.4% in the culture group to 22.5% in the PCR cohort. These savings reflect PCR's ability to enable earlier, more targeted therapy, diminish broad spectrum antibiotic use, and avert costly complications and readmissions. Such multidimensional value (clinical, operational, and economic) is critical to adopting guidelines and payer support for PCR testing in cUTI care. THE PATH FORWARD: IMPLICATIONS AND NEXT STEPS The robust evidence from the NCT06996301 clinical trial and RWE studies marks a pivotal moment in cUTI diagnostics, demanding a re-evaluation of current practices and a clear roadmap for the future. The question is no longer if PCR is superior, but how we integrate this advanced diagnostic into the fabric of routine clinical care to maximize its transformative potential. Clinical Practice Transformation It is understood that adopting PCR panels systemwide presents logistical, billing, and training challenges. To facilitate practical implementation, a parallel combination of PCR and conventional C&S testing should be considered for patients with cUTIs. Implementing this combined strategy represents a paradigm shift in cUTI management, moving from empiric, delayed therapy to precision medicine. Rapid PCR results empower clinicians to: - Initiate targeted therapy sooner: By identifying pathogens and resistance genes within 24 to 48 hours, PCR performed in parallel with culture enables clinicians to initiate targeted, narrow-spectrum antibiotic therapy much earlier—often by day 1. Although culture continues to be processed to confirm or adjust therapy, the availability of rapid PCR results helps minimize delays and reduce treatment failures. This dual-testing approach supports faster recovery, better stewardship, and lowers the risk of resistance development. - Enhance antimicrobial stewardship: The precise information provided by PCR in conjunction with phenotypic culture confirmation facilitates de-escalation of therapy, minimizes inappropriate antibiotic use, and helps preserve the efficacy of existing antimicrobial agents. This combined methodology is a critical step in combating multidrug resistance, especially in cUTI, where resistance rates are high and broad spectrum overuse is rampant. - Improve patient stratification and management: Detecting polymicrobial infections and subtle resistance patterns through PCR while retaining culture for confirmation and phenotypic resistance surveillance allows for more nuanced, personalized treatment plans. This dual-modality approach reduces the likelihood of treatment failure and recurrent infections, ultimately improving patient outcomes and quality of life. Future Research Directions While NCT06996301 and other RWE studies provide a strong foundation, several critical questions warrant further investigation: - Utility in specific subgroups: Further research should explore the optimal utility of PCR in specific patient populations, such as immunocompromised individuals and pediatric patients, where diagnostic challenges are particularly acute and the consequences of delayed or inappropriate treatment are severe. - Integration with advanced analytics: Investigating the integration of PCR data and other molecular tools (sequencing) with artificial intelligence and machine learning algorithms could lead to predictive analytics for treatment response, resistance trends, and even personalized risk assessment for cUTI, moving beyond reactive diagnostics to proactive management. - Comparative effectiveness and cost-benefit in diverse settings: While Ko et al8 provided health economic RWE, further studies are needed to evaluate the cost-effectiveness and clinical benefits of PCR across diverse healthcare settings, including outpatient clinics, long-term care facilities, and acute care hospitals, to inform broader implementation strategies and ensure equitable access. Policy and Implementation For PCR to realize its full potential, concerted efforts are needed to address policy and implementation challenges, ensuring equitable access and seamless integration into healthcare systems: - Guideline integration: Professional societies, including the AUA and Infectious Diseases Society of America, should consider reviewing and updating their cUTI management guidelines to include the parallel use of PCR and C&S testing as a unified diagnostic strategy, reflecting the latest evidence. This dual-testing recommendation would provide clear, evidence-based guidance for clinicians and standardize practice across institutions. - Overcoming implementation barriers: Practical strategies should be developed to support cotesting workflows, including initial capital investment for laboratory infrastructure, cross-training laboratory personnel and clinicians on interpreting molecular and phenotypic results, and the integration of combined PCR and C&S data into electronic medical records to ensure efficient workflow and data utilization. - Payer engagement and innovative reimbursement models: Continued engagement with payers is essential to ensure consistent and equitable reimbursement for PCR testing, recognizing that it has demonstrated clinical utility and cost-effectiveness. This involves developing new reimbursement models that account for the downstream savings generated by PCR, such as reduced hospitalizations and complications. CONCLUSIONS The robust evidence from the NCT06996301 trial and supporting real-world studies unequivocally supports the integration of PCR into cUTI care. This level of evidence parallels the standard required by the FDA to approve new therapies or recommend practice changes. To mitigate the logistical, billing, and training challenges associated with systemwide PCR adoption, a combined approach, performing PCR in parallel with conventional C&S testing, offers a practical, evidence-based pathway to enhance diagnostic speed and accuracy while preserving the benefits of conventional methods (https://links.lww.com/JU9/A150). This foundational advance, much like the evolution of diabetes diagnostics, deserves serious consideration by clinicians, guideline committees, and payers. Embracing a dual-testing paradigm will pave the way for a more precise, efficient, and effective approach to combating complicated and recurrent urinary tract infections while safeguarding the future of antimicrobial efficacy. FUNDING The author declares that no funds, grants, or other support were received during the preparation of this manuscript. CONFLICT OF INTEREST DISCLOSURES The author declares no conflicts. ETHICS STATEMENT This is a commentary article based entirely on previously published data, and therefore IRB approval was not required. No new human subjects research was conducted, and all findings discussed are drawn from publicly available, peer-reviewed sources cited within the manuscript. DATA AVAILABILITY All data analyzed in this commentary are derived from published studies. The data sets used or analyzed during the current study are publicly available from the respective sources cited in the article. No original data were collected or generated specifically for this review. AUTHOR CONTRIBUTIONS Conceptualization: Kardjadj. Investigation: Kardjadj. Writing—review & editing: Kardjadj.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.